• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, June 23, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

One size doesn’t fit all, when using hormone therapy to treat endometriosis

Bioengineer by Bioengineer
October 25, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Endometriosis — a condition caused by uterine tissue growing outside of the organ — affects 10% of reproductive-aged women, whom it causes chronic pain that is significant and debilitating. The standard first-line treatment for all women with endometriosis is hormonal, specifically progestin-based, therapy.

Yet a team of researchers at Yale has shown that the effectiveness of progestin-therapy depends on whether a woman's endometriotic lesions have the progesterone receptor (PR) present. This study appears online in the Journal of Clinical Endocrinology & Metabolism.

The researchers tested the endometriotic lesions of 52 women who had undergone surgical evaluation for endometriosis at Yale New Haven Hospital for their PR status. They found a significant association between PR status and responsiveness to progestin-therapy. Those whose endometriotic lesions were PR-positive responded much better to the progestin-therapy, while those whose lesions were PR-negative found little relief from progestin-therapy alone.

From these findings, the research team concluded that knowing a woman's PR-status may help them develop a "novel, targeted, precision-based" approach to treating and managing endometriosis individually. "Receptor status in endometriosis could be used in a manner analogous to the use of estrogen/progesterone receptor status in breast cancer for tailoring hormonal-based regimens," said Dr. Valerie Flores, first author and clinical instructor at the Yale School of Medicine.

"Such an approach to endometriosis management would make trialing progestin-based therapy to determine response unnecessary," said Flores, "and would therefore minimize delays in providing the optimal medical therapy for each individual patient."

###

This study was funded by a grant from the National Institutes of Health. Other authors on this study include Arne Vanhie, Tran Dang, and Hugh Taylor.

Media Contact

Kendall Teare
[email protected]
203-836-4226
@yale

http://www.yale.edu

https://academic.oup.com/jcem/advance-article/doi/10.1210/jc.2018-01227/5139742

Related Journal Article

http://dx.doi.org/10.1210/jc.2018-01227

Share12Tweet7Share2ShareShareShare1

Related Posts

Phototherapy Alters Urinary Nitric Oxide in Premature Infants

June 23, 2026

Lipid Biomarkers Identified for Parkinson’s in Blood

June 23, 2026

Antimicrobial Stewardship Boosts Neonatal ICU Care Collaboration

June 23, 2026

AMPK/SIRT1 Activation Boosts PGC-1α/PPARγ to Combat Sepsis Weakness

June 23, 2026
Please login to join discussion

POPULAR NEWS

  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates

    92 shares
    Share 36 Tweet 23
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Neonatal Glucose Estimation via Hemoglobin Phase Delay

Phototherapy Alters Urinary Nitric Oxide in Premature Infants

Lipid Biomarkers Identified for Parkinson’s in Blood

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.